Does metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO study.
In a subanalysis on the metformin, arterial function, intima-media thickness, and nitroxidation in the metabolic syndrome (MEFISTO)(8) (an open-label fashion, with 1 year of 850 mg daily of metformin) subjects' samples, we measured the paraoxonase 1 (PON1) activity in 39 patients that finished the study and relate values with high density lipoprotein (HDL). The comparative PON1 activities at the beginning and at the end of the study were 5.528 ± 0.588 and 4.743 ± 0.619 nmol/mg protein/min (NS) for control group and 3.229 ± 0.403 and 5.135 ± 0.585 nmol/mg protein/min (p < 0.02) for the metformin group. Our data showed an enhance of PON1 activity in patients with metabolic syndrome treated with metformin, although in them, the raise of HDL concentration was less than control patients, suggesting that the increase in quality (measured here as PON1 activity) could be at least as important as an increase in its concentration. Our results point out that there is a relationship among PON1 activity and the reduction of carotideal intima-media thickness.
Cardiovascular Unit, Regional Hospital 1o de Octubre, ISSSTE, Mexico City, Mexico. lalitomini@prodigy.net.mx
Eduardo
E
Meaney
Patricia
P
Sierra-Vargas
Alejandra
A
Meaney
Martín
M
Guzmán-Grenfell
Israel
I
Ramírez-Sánchez
Juan Jose
JJ
Hicks
Ivonne
I
Olivares-Corichi
Guillermo
G
Ceballos
D043303:Aryldialkylphosphatase / Q000378:metabolism*; D059168:Carotid Intima-Media Thickness; D016022:Case-Control Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology*; D008687:Metformin / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D008075:Lipoproteins, HDL; D008687:Metformin; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human